Engineered MSC Aggregates with E/N‐Cadherin and IL‐6 Preconditioning for the Treatment of Systemic Sclerosis
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202500663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Yue Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, 321 Zhongshan Road, Nanjing, 210008, P…. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Mesenchymal Stem Cells, Interleukin-6, Cadherins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Postgraduate Research & Practice Innovation Program of Jiangsu Province.
Abstract (Originalsprache)
Umbilical cord‐derived mesenchymal stromal cells (MSCs) transplantation is a promising therapy for systemic sclerosis (SSc) because of their distinctive antifibrotic and immunomodulatory properties. To enhance the effects of MSCs transplantation, novel engineered MSC aggregates preconditioned with human E/N‐cadherin fusion protein (hE/N‐cad‐Fc) and interleukin‐6 (IL‐6) for SSc treatment are fabricated and named 3D‐Cad/IL6‐MSCs. These novel‐engineered MSC aggregates possess tighter cellular cohesion and exhibit enhanced antiapoptotic, immunosuppressive, and proangiogenic capabilities according to transcriptomic analyses. Moreover, 3D‐Cad/IL6‐MSCs have improved immunoregulatory effects on peripheral blood mononuclear cells (PBMCs), CD4 + T cells, and CD8 + T cells in vitro because of the synergistic preconditioning from IL‐6 and bioactive hE/N‐cad‐Fc. Upon intravenous injection, 3D‐Cad/IL6‐MSCs significantly mitigate skin and lung fibrosis and prolong the retention duration in bleomycin (BLM)‐induced SSc mouse model. In detail, they suppress excessive infiltration of macrophages and T cells in the injured skin and lungs and reestablish the immune equilibrium of circulating CD4 + T‐cell subsets in vivo. These results suggest that 3D‐Cad/IL6‐MSCs are ideal candidates for SSc therapy and optimize the clinical utilization of MSCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, 321 Zhongshan Road, Nanjing, 210008, P. R. China.
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Science, Nankai University, 94 Weijin Road, Tianjin, 300071, P. R. China.
- Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, 321 Zhongshan Road, Nanjing, 210008, P. R. China.
- Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, 321 Zhongshan Road, Nanjing, 210008, P. R. China.
- Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, P. R. China.
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, 230022, P. R. China.
ORCID-Profile: Shanshan Liu, Lingyun Sun
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
Zitieren
APA
Zhang, Y., Qian, M., Shi, Y., Cao, J., Xu, M., Wen, X., Yan, Y., Liu, S., Chen, H., Liu, S., Yang, J., & Sun, L. (2025). Engineered MSC Aggregates with E/N‐Cadherin and IL‐6 Preconditioning for the Treatment of Systemic Sclerosis. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500663
Vancouver
Zhang Y, Qian M, Shi Y, Cao J, Xu M, Wen X, et al. Engineered MSC Aggregates with E/N‐Cadherin and IL‐6 Preconditioning for the Treatment of Systemic Sclerosis. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500663
BibTeX
@article{Zhang2025,
author = {Zhang, Yue and Qian, Mengyuan and Shi, Yirui and Cao, Jiaxu and Xu, Min and Wen, Xin and Yan, Yunxia and Liu, Sha and Chen, Hongwei and Liu, Shanshan and Yang, Jun and Sun, Lingyun},
title = {Engineered MSC Aggregates with E/N‐Cadherin and IL‐6 Preconditioning for the Treatment of Systemic Sclerosis},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202500663}
}
EUVIMED